Patents by Inventor Michael Anthony Cawthorne
Michael Anthony Cawthorne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130245110Abstract: The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.Type: ApplicationFiled: January 7, 2013Publication date: September 19, 2013Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Michael Anthony Cawthorne, Saoirse O'Sullivan
-
Publication number: 20130165446Abstract: The present invention addresses the problem of finding a compound having both PPAR activation activity and angiotensin receptor antagonistic activity. The present invention is a benzo- or pyrido-imidazole derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, or a ester or amide thereof (where A is biphenyl methyl-imidazolyl, biphenyl methyl-benzimidazolyl, or the like, B is divalent benzimidazolyl or the like, C is carboxyl or the like, E is divalent phenyl, naphthyl, or the like, G is a dangling bond, oxygen, or the like, Q is oxygen or sulfur, n is an integer from 1 to 6, p is an integer from 1 to 6, V is a dangling bond, oxygen, or the like, and R is hydrogen, alkyl, or the like).Type: ApplicationFiled: May 11, 2011Publication date: June 27, 2013Inventors: Takashi Fujita, Hiroyoshi Horikoshi, Michael Anthony Cawthorne
-
Publication number: 20110082195Abstract: The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.Type: ApplicationFiled: January 21, 2009Publication date: April 7, 2011Applicant: GW PHARMA LIMITEDInventors: Geoffrey Guy, Stephen Wright, Michael Anthony Cawthorne, Saoirse O'Sullivan
-
Patent number: 7662784Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction or body weight in a human or mammalian animal.Type: GrantFiled: November 29, 2005Date of Patent: February 16, 2010Assignee: Ipsen Pharma, S.A.S.Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
-
Patent number: 7416744Abstract: The invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity.Type: GrantFiled: October 13, 2005Date of Patent: August 26, 2008Assignee: Conopco, Inc.Inventors: Ian Duncan Rubin, Jasjit Singh Bindra, Michael Anthony Cawthorne
-
Patent number: 7256174Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X by administering a therapeutically effective amount of a somatostatin agonist or a pharmaceutical composition comprised of a somatostatin agonist to a patient suffering from insulin resistance or Syndrome X.Type: GrantFiled: February 18, 2003Date of Patent: August 14, 2007Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
-
Patent number: 7034003Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction of body weight in a human or mammalian animal.Type: GrantFiled: May 13, 1998Date of Patent: April 25, 2006Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SASInventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
-
Patent number: 7033616Abstract: The invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity.Type: GrantFiled: June 27, 2001Date of Patent: April 25, 2006Assignee: Phytopharm PLCInventors: Ian Duncan Rubin, Jasjit Singh Bindra, Michael Anthony Cawthorne
-
Patent number: 7026289Abstract: The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.Type: GrantFiled: May 13, 1998Date of Patent: April 11, 2006Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SASInventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
-
Patent number: 6774109Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor (“SSTR-5”) and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyperamylinemia with a ligand selective for SSTR-5.Type: GrantFiled: October 31, 1997Date of Patent: August 10, 2004Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.Inventors: Simon Jon Dunmore, Michelle Davenport, Michael Anthony Cawthorne
-
Publication number: 20040146951Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor (“SSTR-5”) and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyperamylinemia with a ligand selective for SSTR-5.Type: ApplicationFiled: January 8, 2004Publication date: July 29, 2004Inventors: Simon Jon Dunmore, Michelle Davenport, Michael Anthony Cawthorne
-
Publication number: 20040072734Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. The invention also includes pharmaceutical compositions comprising a somatostatin or somatostatin agonist and the use of such products in the preparation of such compositions.Type: ApplicationFiled: February 18, 2003Publication date: April 15, 2004Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
-
Publication number: 20020151500Abstract: The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols. glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.Type: ApplicationFiled: March 20, 2000Publication date: October 17, 2002Inventors: MICHAEL ANTHONY CAWTHORNE, YONG-LING LIU, MATTHEW V. SENNITT
-
Publication number: 20020146468Abstract: The invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity.Type: ApplicationFiled: June 27, 2001Publication date: October 10, 2002Inventors: Ian Duncan Rubin, Jasjit Singh Bindra, Michael Anthony Cawthorne
-
Publication number: 20020042374Abstract: The present invention relates to a method of treating insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient.Type: ApplicationFiled: May 13, 1998Publication date: April 11, 2002Inventors: MICHAEL ANTHONY CAWTHORNE, YONG-LING LIU, MATTHEW V. SENNITT
-
Publication number: 20010006790Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor (“SSTR-5”) and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyperamylinemia with a ligand selective for SSTR-5.Type: ApplicationFiled: October 31, 1997Publication date: July 5, 2001Inventors: SIMON JON DUNMORE, MICHELLE DAVENPORT, MICHAEL ANTHONY CAWTHORNE
-
Patent number: 6004928Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to the patient.Type: GrantFiled: May 13, 1998Date of Patent: December 21, 1999Assignee: Biomeasure, IncorporatedInventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
-
Patent number: 5763200Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor ("SSTR-5") and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyper-amylinemia with a ligand selective for SSTR-5.Type: GrantFiled: May 12, 1995Date of Patent: June 9, 1998Assignee: Biomeasure, IncorporatedInventors: Simon Jon Dunmore, Michelle Davenport, Michael Anthony Cawthorne
-
Patent number: 4055635Abstract: Fibrinolytic pharmaceutical compositions are provided in unit dosage form and comprise a water-soluble complex of a proteolytic enzyme linked covalently to a polymeric substance.Type: GrantFiled: July 2, 1974Date of Patent: October 25, 1977Assignee: Beecham Group LimitedInventors: Joseph Green, Michael Anthony Cawthorne